Evidence map›Paper›PMID 31039677›Full record

ArticleSLAS discovery : advancing life sciences R & D2019

Developing Colorimetric and Luminescence-Based High-Throughput Screening Platforms for Monitoring the GTPase Activity of Ferrous Iron Transport Protein B (FeoB).

John Veloria, Minhye Shin, Ashwini K Devkota, Shelley M Payne, Eun Jeong Cho, Kevin N Dalby

Open access · hybridAbstract read
In one paragraph

Article in SLAS discovery : advancing life sciences R & D, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Vanadate inhibits Feo-mediated iron transport in Vibrio cholerae.Metallomics : integrated biometal science · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

John Veloria1 Targeted Therapeutic Drug Discovery and Development Program, College of Pharmacy, The University of Texas at Austin, Austin, TX, USA.
Minhye Shin2 Department of Molecular Biosciences, College of Natural Science, The University of Texas at Austin, Austin, TX, USA.
Ashwini K Devkota1 Targeted Therapeutic Drug Discovery and Development Program, College of Pharmacy, The University of Texas at Austin, Austin, TX, USA.
Shelley M Payne2 Department of Molecular Biosciences, College of Natural Science, The University of Texas at Austin, Austin, TX, USA.
Eun Jeong Cho1 Targeted Therapeutic Drug Discovery and Development Program, College of Pharmacy, The University of Texas at Austin, Austin, TX, USA.
Kevin N Dalby1 Targeted Therapeutic Drug Discovery and Development Program, College of Pharmacy, The University of Texas at Austin, Austin, TX, USA.
Target (United States) · USThe University of Texas at Austin · US

Funding

Characterization of the ferrous iron transporter Feo in Vibrio choleraeR01AI091957 · NIAID · UNIVERSITY OF TEXAS AT AUSTIN · PI PAYNE, SHELLEY M. · 2011 to 2021
$3.9M
NIAID NIH HHS R01 AI091957
6 · The paper itself

Abstract

Iron is an essential requirement for the survival and virulence for bacteria. The bacterial ferrous iron transporter protein B (FeoB) functions as a major iron transporter in prokaryotes and has an N-terminal domain (NFeoB) with homology to eukaryotic G-proteins. Its GTPase activity is required for ferrous iron uptake, making it a potential target for antivirulence therapies. Here, two assay strategies relying on different spectroscopic readouts are described to monitor NFeoB GTPase activity. The first one is the colorimetric-based platform that utilizes a malachite green reagent to monitor phosphate production from GTP hydrolysis. The absorbance change directly relates to the GTPase activity of NFeoB. The assay was further improved by the addition of Tween-20 and miniaturized in a 384-well plate format with a 10 µL assay volume. The second format is a luminescence-based platform, measuring the GTP depletion by using a modified GTPase-Glo assay from Promega. In this platform, the luminescence signal correlates to the amount of GTP remaining, allowing for the direct calculation of GTP hydrolysis by NFeoB. The colorimetric platform was tested in a high-throughput manner against a custom-assembled library of a~2000 small molecules and was found to be simple, cost-effective, and robust. Additionally, the luminescence-based platform demonstrated its capability as an orthogonal assay to monitor GTPase activity, providing a valid and convenient method to filter false hits. These two assay platforms are proven to offset the limitations of each platform while enhancing overall quality and success rates.

Indexed as

High-Throughput Screening AssaysAmino Acid SequenceCation Transport ProteinsColorimetryEscherichia coliEscherichia coli ProteinsGTP PhosphohydrolasesGuanosine TriphosphateHydrolysisLuminescenceModels, MolecularProtein DomainsSmall Molecule LibrariesCation Transport ProteinsEscherichia coli ProteinsFeoB protein, E coliGTP PhosphohydrolasesGuanosine TriphosphateSmall Molecule LibrariesGTPasehigh-throughput screeninginhibitorluminescencemalachite greenNFeoB

Identifiers

PMID31039677
PMCPMC6714053
OpenAlexW2943028438

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.